Florida Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals

Florida Medicaid covers Mounjaro, Ozempic, and Trulicity as Preferred GLP-1 receptor agonists for type 2 diabetes mellitus, effective April 1, 2026, each requiring Clinical Prior Authorization (HbA1c ≥ 6.5%, metformin trial-and-failure, age thresholds). Florida does NOT cover Wegovy, Zepbound, or Saxenda for chronic weight management — but unlike Texas (which has an explicit “Non-Covered Benefit” provider notice) or New York (which has a triple-anchored explicit regulatory exclusion), Florida's coverage stance is established by operational silence: Wegovy, Zepbound, and Saxenda are simply absent from the April 1, 2026 Florida Medicaid Preferred Drug List, the March 12, 2026 GLP-1 Receptor Agonist Prior Authorization Criteria, and the April 30, 2026 Summary of Drug Limitations. No single AHCA bulletin explicitly labels these drugs “Non-Covered Benefit.” All five major Statewide Medicaid Managed Care (SMMC) plans — Sunshine Health, Humana Healthy Horizons, Simply Healthcare, Molina Healthcare, and Aetna Better Health — explicitly defer to the AHCA PDL via verbatim deferral language in their pharmacy-benefit pages. The federal optional weight-loss exclusion at 42 U.S.C. § 1396r-8(d)(2)(A) is the operative authority. Florida is not among the 13 state Medicaid programs that the KFF January 2026 tracker identifies as covering GLP-1s for obesity under fee-for-service. Two 2026 Florida legislative bills (SB 1070 and HB 977) targeted the State Group Insurance program for state employees — not Medicaid — and both died in committee on March 13, 2026.

What Florida Medicaid covers (the bottom line)

Florida Medicaid's GLP-1 coverage is strictly limited to the type 2 diabetes indication. As of the April 1, 2026 PDL revision and the March 12, 2026 GLP-1 Receptor Agonist Prior Authorization Criteria:

• Preferred GLP-1s for T2D (Clinical PA Required): Mounjaro (tirzepatide, age ≥ 10), Ozempic (semaglutide, age ≥ 18), and Trulicity (dulaglutide, age ≥ 10). All three require Clinical Prior Authorization with the full five-criterion checklist (see PA criteria below).
• Non-preferred GLP-1s for T2D (Clinical PA Required + step-therapy): Exenatide (Byetta, Bydureon, Bydureon BCise), liraglutide / Victoza, and Rybelsus (oral semaglutide). These require all preferred-agent criteria plus documentation of a previous trial with insufficient response, adverse reaction, or contraindication to a preferred GLP-1.
• Wegovy, Zepbound, Foundayo: NOT listed in the April 1, 2026 PDL, the March 12, 2026 GLP-1 Criteria PDF, or the April 30, 2026 Drug Limitations document. No Florida Medicaid PA pathway exists under the GLP-1 class criteria for the chronic-weight-management indication.
• Saxenda (liraglutide 3 mg): not listed on the PDL or in the GLP-1 Criteria PDF. Saxenda does appear in the Drug Limitations document with a minimum-age requirement of 12 — but that entry alone does not establish coverage. A Saxenda PA submission would be evaluated under the Miscellaneous Drug Criteria's “medically accepted indication” gate, which the chronic-weight-management indication does not satisfy under Florida's invocation of the federal optional exclusion.
• Imcivree (setmelanotide): the only obesity-indicated drug with a published Florida Medicaid PA pathway — restricted to monogenic / syndromic genetic-cause obesity (POMC, PCSK1, LEPR deficiency or Bardet-Biedl syndrome), not general adult obesity. Endocrinologist or rare-genetic-disorder expert required; confirmed genetic testing required.
• Foundayo (LillyDirect tirzepatide): out-of-scope for Florida Medicaid. Foundayo is a cash-pay direct-to-consumer brand from Eli Lilly that does not bill insurance; PDL status is irrelevant to the Foundayo patient pathway.

Florida's silent exclusion: coverage established by operational absence, not by a single AHCA bulletin

The single most important structural feature of Florida's GLP-1 coverage landscape — and the feature that distinguishes it from every other state in this 50-state Medicaid series — is that Florida's exclusion of GLP-1s for chronic weight management is operational by absence, not by an explicit “Non-Covered Benefit” notice or state-regulation hook.

Florida has not published a single-document explicit “Non-Covered Benefit” notice for Wegovy, Zepbound, or Saxenda comparable to Texas's Superior HealthPlan June 2023 notice or California's Medi-Cal Rx December 12, 2025 alert. Florida's coverage stance is established by the operational silence of four primary-source documents, each reviewed in full (verified July 2026):

1. No Wegovy, Zepbound, or Foundayo entry anywhere in the April 1, 2026 PDL.
2. No Wegovy, Zepbound, Saxenda, or Foundayo entry in the March 12, 2026 GLP-1 Receptor Agonist Prior Authorization Criteria (verified — only Mounjaro / Ozempic / Trulicity preferred and Exenatide / Liraglutide / Victoza / Rybelsus non-preferred are addressed).
3. No standalone obesity-indication criteria document at ahca.myflorida.com/medicaid/prescribed-drugs/drug-criteria for Wegovy, Zepbound, or Saxenda (verified — only Imcivree for genetic obesity and Myalept for leptin deficiency are present as obesity-indicated documents).
4. Wegovy, Zepbound, and Foundayo are absent from the April 30, 2026 Summary of Drug Limitations. Saxenda appears with a minimum-age-12 entry only.

Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

Federal Medicaid drug-coverage rules permit — but do not require — states to exclude certain enumerated categories of drugs from coverage. The category that matters for Wegovy, Zepbound, and Saxenda when prescribed for chronic weight management is at 42 U.S.C. § 1396r-8(d)(2)(A). Verbatim from Cornell Legal Information Institute (verified July 2026):

“Agents when used for anorexia, weight loss, or weight gain.”

This is one of seven enumerated optional-exclusion categories in the statute. The federal floor: states may decline Medicaid coverage of any drug when prescribed for one of these uses. The federal ceiling: states may elect to cover them anyway — nothing prohibits state coverage. Florida has elected to use the optional exclusion for weight-loss-indication GLP-1s — exercised by operational practice (PDL absence + GLP-1 Criteria silence + Miscellaneous Criteria's “medically accepted indication” gate) rather than by an explicit AHCA policy statement.

The Florida Medicaid PDL: verbatim GLP-1 entries (effective April 1, 2026)

The operative primary source is the Florida Medicaid Preferred Drug List — Effective April 1, 2026, published by AHCA (verified May 2026).

PDL header text (verbatim):

“The Florida Medicaid Preferred Drug List (PDL) is subject to revision following consideration and recommendations by the Pharmaceutical & Therapeutics (P&T) Committee and the Agency for Health Care Administration.”

PA column definition (verbatim):

“Clinical PA — These drugs require prior authorization submission that must include clinical documentation. The drugs that require clinical prior authorization review and the prior authorization forms can be found in this link: https://ahca.myflorida.com/medicaid/prescribed-drugs/medicaid-pharmaceutical-therapeutics-committee/pharmacy-prior-authorization-forms”

Class C4I — ANTIHYPERGLY, INCRETIN MIMETIC (GLP-1 RECEP. AGONIST): verbatim preferred entries

The following drugs appear verbatim in the April 1, 2026 PDL under the Incretin Mimetic (GLP-1 Receptor Agonist) class:

Class C4Z — ANTIHYPERGLYCEMIC — INCRETIN MIMETICS COMBINATION: verbatim Mounjaro entries

Mounjaro (tirzepatide — a dual GIP / GLP-1 receptor agonist) appears in a separate class for the T2D indication:

Crucially: the April 1, 2026 PDL lists only preferred entries. Non-preferred drugs (Exenatide, Liraglutide/Victoza, Rybelsus) are not enumerated on the PDL itself; they are documented in the class-specific GLP-1 PA Criteria PDF (see PA criteria ). Drugs with no entry in either the PDL or the GLP-1 Criteria PDF (Wegovy, Zepbound, Foundayo) fall under the federal weight-loss optional-exclusion authority and have no PA pathway under the GLP-1 class criteria.

PDL status is subject to change at the next revision cycle. The Florida P&T Committee meets quarterly under Florida Statute 409.91195. The April 1, 2026 PDL reflects recommendations from the December 12, 2025 P&T Committee meeting. The next scheduled revision will reflect subsequent quarterly meeting recommendations.

Florida Medicaid GLP-1 Prior Authorization Criteria: verbatim 5-criterion checklist

The canonical operational document is the GLP-1 Receptor Agonist Prior Authorization Criteria, March 12, 2026 (Florida AHCA Division of Pharmacy Policy; original June 16, 2025; revised October 1, 2025, October 8, 2025, March 12, 2026). Document title (verbatim):

“Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual glucose-dependent insulinotropic polypeptide (GIP) receptor/GLP-1 Receptor Agonists”

Preferred / Non-preferred classification (verbatim):

“Preferred agents (Clinical Prior Authorization Required): Mounjaro® (tirzepatide), Ozempic® (semaglutide), and Trulicity® (dulaglutide)”

“Non-preferred agents: Exenatide, liraglutide (generic for Victoza), Rybelsus® (semaglutide), and Victoza® (liraglutide)”

Length of authorization (verbatim):

“LENGTH OF AUTHORIZATION: Up to one year”

Initial review criteria (all five criteria must be met)

The initial review criteria are verbatim from the March 12, 2026 GLP-1 Criteria document (note the AND connectors — all criteria must be met simultaneously):

“REVIEW CRITERIA:
• Patient must be ≥ 18 years of age for Ozempic, and Rybelsus, or patient must be ≥ 10 years of age for Mounjaro, Trulicity and Victoza; AND
• Patient must have a diagnosis of type 2 diabetes mellitus; AND
• Hemoglobin A1C (HbA1c) ≥ 6.5% measured within the past 6 months (documentation required); AND
• Patient must have trial and failure of metformin within the past 2 years unless contraindicated or the patient is intolerant to treatment (documentation required); AND
• Patient must have previous trial with insufficient response, adverse reaction, or contraindication to preferred GLP-1 Receptor Agonists if the request is for non-preferred agents (documentation required).”

Continuation of therapy criteria

Continuation of therapy (verbatim from March 12, 2026 GLP-1 Criteria):

“CONTINUATION OF THERAPY
• Patient met initial review criteria; AND
• Documentation of improved clinical response (e.g., decline in HbA1c); AND
• Patient has not experienced any treatment-restricting adverse effects; AND
• Dosing is appropriate as per labeling or is supported by compendia.”

Per-drug coverage status table

Saxenda anomaly: Drug Limitations entry without PDL or GLP-1 Criteria coverage

Saxenda (liraglutide 3 mg, prescribed for chronic weight management) presents an unusual situation. It is absent from both the April 1, 2026 PDL and the March 12, 2026 GLP-1 Criteria PDF — but it does appear in the Florida Medicaid Summary of Drug Limitations (April 30, 2026). Verbatim from the Drug Limitations document:

“Saxenda (liraglutide) pen — Minimum age = 12”

This Drug Limitations entry alone does not establish Saxenda coverage. The Drug Limitations document captures age and quantity rules for drugs that are billed through Florida Medicaid — but the absence of Saxenda from the PDL and the GLP-1 Criteria PDF means a Saxenda PA submission would be evaluated against the Miscellaneous Drug Criteria (Revision Date January 21, 2026) rather than the GLP-1 class criteria. Verbatim from the Miscellaneous Drug Criteria:

“INITIAL REVIEW CRITERIA:
• The patient has tried and failed medications on the Preferred Drug List or there is a reason (allergy, contraindication) that preferred drugs cannot be used; AND
• Documentation of previous trials such as progress notes, diagnostic evaluations and lab results are required; AND
• If the request is for a brand name drug and the generic is preferred, a trial of the generic drug or rationale why the generic cannot be used is required; AND
• The drug is requested for a medically accepted indication; AND
• Dosage and administration does not exceed FDA approved maximum for the patient's indication.”

The operative gate is the fourth criterion: “medically accepted indication.” Under federal Medicaid drug-rebate law, a “medically accepted indication” excludes any indication that falls within a state's elected optional- exclusion category. Because Florida exercises the optional weight-loss exclusion at 42 U.S.C. § 1396r-8(d)(2)(A), a Saxenda PA for chronic weight management would not satisfy the “medically accepted indication” criterion. Do not interpret the Saxenda Drug Limitations entry as evidence of coverage; it is not.

The five SMMC plan-level deferral statements

Florida moved most Medicaid recipients into Statewide Medicaid Managed Care (SMMC) plans starting in 2014. The current cycle, SMMC 3.0, began February 1, 2025 and runs through 2029. Approximately 71% of Florida Medicaid recipients are enrolled in managed-care plans (an AHCA-cited statistic; the precise current figure was not re-confirmed against the AHCA enrollment dashboard in our May 2026 review).

The critical finding: all major SMMC plans explicitly defer to the AHCA PDL for GLP-1 pharmacy coverage. Each plan's pharmacy-benefit page was verified in May 2026 (except Aetna Better Health, whose statement could not be confirmed against the plan's own site and is summarized from its public materials, with hedging noted below).

Sunshine Health (Centene)

Primary source: Sunshine Health provider pharmacy page (sunshinehealth.com/providers/pharmacy.html, verified July 2026). Verbatim:

“Sunshine Health follows the Agency for Health Care Administration (AHCA) Preferred Drug List (PDL) guidelines.”

“Every quarter, the PDL is revised according to the recommendations of the AHCA Pharmaceutical and Therapeutics (P&T) Committee.”

“Sunshine Health works with Express Scripts to process all pharmacy claims for prescribed drugs.”

Humana Healthy Horizons in Florida

Primary source: Humana Florida Medicaid pharmacy page (humana.com/medicaid/florida-medicaid/coverage/pharmacy, verified July 2026). Verbatim:

“These medicines are part of a formulary, or Preferred Drug List (PDL).”

“The AHCA Preferred Drug List includes the same information as our Preferred Drug List, including any changes.”

“Some medicines on the PDL may be limited or require approval.”

Simply Healthcare (Elevance / Anthem)

Primary source: Simply Healthcare Florida Medicaid pharmacy page (simplyhealthcareplans.com/florida-medicaid/benefits/pharmacy-benefits.html, verified July 2026). Verbatim:

“Florida Medicaid members We use the Florida Medicaid Preferred Drug List (PDL).”

“The Supplemental Preferred Drug List (PDL) includes drugs the Simply pharmacy benefit covers that are not listed on the Agency For Health Care Administration (AHCA) PDL and sometimes require preapproval or prior authorization (PA). We work with CarelonRx to provide these pharmacy benefits.”

Molina Healthcare of Florida

Primary source: Molina Healthcare of Florida member prescription drugs page (molinahealthcare.com/members/fl/en-us/mem/medicaid/overvw/coverd/presdrugs.aspx, verified July 2026). Verbatim:

“Molina Healthcare uses a Preferred Drug List (PDL) for Medicaid, which is a list of covered prescription drugs that is reviewed, approved and maintained by a team of doctors and pharmacists at the State of Florida.”

“Drugs not listed on the PDL are called non-formulary drugs.”

“Molina has selected CVS Health as the Pharmacy Benefits manager (PBM) company to manage the prescription benefit for Molina members.”

Aetna Better Health of Florida (coverage unverified)

[reported by the plan's public materials; not independently verified] “Aetna Better Health of Florida covers all items, services and drugs that AHCA decides to include as covered benefits.”

This snippet is directionally consistent with the explicit PDL- deferral statements of the four other major SMMC plans, but readers should verify current Aetna Better Health pharmacy benefit information directly at aetnabetterhealth.com/florida or by calling Aetna Better Health member services.

No plan-level PA divergence verified. The “supplemental PDL” structure used by Sunshine, Simply, and Aetna is for non-classified, non-controversial fill-in coverage — not for circumventing the state's invocation of the federal weight-loss exclusion. No verified primary source supports a claim that any individual SMMC plan covers Wegovy, Zepbound, or Saxenda for the weight-loss indication independent of the AHCA state PDL.

The Florida P&T Committee: statutory framework and recent GLP-1 decisions

The Florida Medicaid Pharmaceutical & Therapeutics (P&T) Committee is the advisory body that drives PDL and PA-criteria revisions. Verbatim from the AHCA P&T Committee landing page (ahca.myflorida.com/medicaid/prescribed-drugs/medicaid-pharmaceutical-therapeutics-committee, verified July 2026):

“The purpose of the Florida Medicaid Pharmaceutical & Therapeutics (P&T) Committee is to develop and implement a Medicaid preferred drug list (PDL), as mandated, originally, in the 2000 session of the Florida legislature.”

“Florida Statute 409.91195 requires the appointment of this committee by the Governor.”

“Upon recommendations by the P&T committee, established pursuant to s. 409.91195, the Agency for Health Care Administration (Agency) shall establish the Florida Medicaid Preferred Drug List (PDL). The Florida Medicaid PDL, shall be a listing of cost-effective, safe and clinically efficient medications for each of the therapeutic classes on the list.”

December 12, 2025 P&T Committee — GLP-1-relevant changes effective April 1, 2026

The only change to the Hypoglycemics / Incretin Mimetics class at the December 12, 2025 P&T Committee meeting was the addition of Brynovin Solution (Oral) to the Non-PDL list. Verbatim from the “Summary of Changes — From the December 12, 2025 Florida Pharmaceutical & Therapeutics Committee Meeting (Changes Effective April 1, 2026)”:

“HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
BRYNOVIN SOLUTION (ORAL)     NA     Non-PDL”

The December 12, 2025 P&T Committee did not make Wegovy, Zepbound, or Saxenda PDL-coverage decisions. These drugs remained in their pre-existing absent-from-PDL state. The “no change” status for the chronic-weight-management indication is itself the verified primary-source finding for the April 1, 2026 PDL cycle.

Critical distinction: T2D-indicated vs weight-loss-indicated GLP-1s

The T2D / weight-loss distinction is load-bearing for understanding Florida Medicaid GLP-1 coverage and must not be conflated. The same molecule (semaglutide) is marketed under two brand names with different FDA-approved indications:

• Ozempic (semaglutide 0.5 mg / 1 mg / 2 mg) — FDA-approved for type 2 diabetes mellitus. Florida Medicaid covers Ozempic under Clinical PA with the T2D-specific criteria above. Covered.
• Wegovy (semaglutide 2.4 mg) — FDA- approved for chronic weight management (BMI ≥ 30, or ≥ 27 with comorbidity), and additionally for cardiovascular event reduction (MACE) and MASH. Florida Medicaid's GLP-1 Criteria document does not address any of these indications. Not covered under the GLP-1 class criteria.

The same pattern applies to tirzepatide:

• Mounjaro (tirzepatide, T2D) — Preferred on the April 1, 2026 PDL. Covered.
• Zepbound (tirzepatide, weight management / obstructive sleep apnea) — not listed in the PDL, GLP-1 Criteria, or Drug Limitations document. Not covered.

Florida AHCA has not published GLP-1 prior-authorization criteria addressing the cardiovascular, MASH, or obstructive sleep apnea indications for Wegovy or Zepbound as of the March 12, 2026 GLP-1 Criteria revision. Patients and providers should expect plan-level Miscellaneous Drug Criteria review on a case-by-case basis for any such submission — and the “medically accepted indication” gate remains a significant barrier under Florida's invocation of the optional federal exclusion.

The genetic-obesity exception: Imcivree (setmelanotide)

Imcivree (setmelanotide) is not a GLP-1 receptor agonist; it is an MC4 receptor agonist. It is included here because it is the only obesity-indicated drug with a published Florida Medicaid Prior Authorization pathway as of this article's publication date — and it applies to a very small clinical population.

Primary source: Imcivree PA Criteria, Florida AHCA Division of Pharmacy Policy, Original Development Date April 30, 2024 (verified July 2026).

Length of authorization (verbatim):

“Proopiomelanocortin (POMC), Proprotein convertase subtilisin/kexin type 1 (PCSK 1), or Leptin receptor (LEPR) deficiency – 16 weeks
Bardet-Biedl syndrome (BBS) – 1 year”

Review criteria (verbatim, POMC / PCSK1 / LEPR deficiency track):

“Patient must be ≥ 6 years of age; AND
Medication is prescribed by or in consultation with an endocrinologist or expert in rare genetic disorders of obesity; AND
Patient must have a diagnosis of monogenic or syndromic obesity as defined by:
  o BMI ≥ 30 kg/m² for adults; OR
  o Bodyweight > 95th percentile for age on growth chart assessment in pediatric patients (< 18 years of age); AND
Documentation obesity is due to POMC, PCSK 1, or LEPR deficiency, confirmed by genetic testing; AND
Genetic testing demonstrates that variants in POMC, PCSK1, or LEPR genes are pathogenic, likely pathogenic, or of uncertain significance.”

Continuation of therapy (verbatim):

“Patient met initial review criteria; AND
Documentation of positive clinical response (e.g., weight loss of 5% of baseline body weight or 5% of baseline BMI); AND
Dosing is appropriate as per labeling or is supported by compendia.”

There is no published PA pathway for general adult obesity using Wegovy, Zepbound, or Saxenda. The Imcivree pathway is relevant only to patients with confirmed monogenic or syndromic genetic- cause obesity and documented genetic testing results.

The 2026 Florida legislative session: SB 1070 and HB 977 (both died March 13, 2026)

In the 2026 Florida Regular Legislative Session, two parallel bills addressed GLP-1 weight-management medication coverage. Neither bill targeted Florida Medicaid. Both bills died in committee on March 13, 2026.

SB 1070 (Senator Rodriguez)

Primary source: flsenate.gov/Session/Bill/2026/1070 (verified July 2026). Bill metadata (verbatim):

“By Senator Rodriguez”
“Subject: State Group Insurance Program Coverage for Obesity Treatment”
“Effective Date: 7/1/2026”
“Last Action: 3/13/2026 Senate - Died in Governmental Oversight and Accountability”

Statutory scope (verbatim from bill text at flsenate.gov/Session/Bill/2026/1070/BillText/Filed/HTML):

“An act relating to state group insurance program coverage for obesity treatment; amending s. 110.12303, F.S.; requiring the Department of Management Services to provide coverage for specified strategies for the evidence-based treatment and management of obesity and related conditions for state group health insurance plan policies issued on or after a specified date; prohibiting coverage criteria for weight management medications from being more restrictive than the United States Food and Drug Administration's indications for such medications...”

SB 1070 amended section 110.12303, F.S., which governs the State Group Insurance Program — the health benefit plan covering Florida state employees and their dependents administered by the Department of Management Services. It did NOT amend Florida Medicaid statutes (chapter 409, under which the GLP-1 PDL is established via Florida Statute 409.91195). SB 1070 would not have changed Florida Medicaid GLP-1 coverage even if enacted.

HB 977 (Representatives Borrero and Valdés)

Primary source: flsenate.gov/Session/Bill/2026/977 (verified July 2026). Bill metadata (verbatim):

“Subject: Benefits for Obesity under the State Group Health Insurance Plan”
“Filed By: Borrero, Valdés”
“Effective Date: 7/1/2026”
“Last Action: 3/13/2026 H Died in Health Care Facilities & Systems Subcommittee”

HB 977 was the House companion to SB 1070 — same statutory scope (state-employee benefit plan under s. 110.12303, F.S., not Medicaid), same die date of March 13, 2026.

What these bills mean for Florida Medicaid patients: nothing. As of this article's publication date, no Florida legislation has been enacted that mandates or expands Florida Medicaid GLP-1 coverage for the weight-loss indication. Do not interpret the 2026 legislative activity as a signal that Florida Medicaid GLP-1 weight-loss coverage is imminent.

CMS BALANCE Model: Florida's participation status is unverified

CMS opened a voluntary state opt-in window for the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model beginning May 2026, running through January 1, 2027. The BALANCE Model would allow participating state Medicaid agencies to cover Wegovy, Zepbound, and other GLP-1s for weight management. Florida AHCA's BALANCE Model participation status is not addressed in any verified primary source. Do not claim Florida is participating in BALANCE without an explicit AHCA or CMS primary source naming Florida.

KFF January 2026 tracker: Florida is not among the 13 states covering GLP-1s for obesity

The KFF “Medicaid Coverage of and Spending on GLP-1s” tracker (published January 16, 2026) identified 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service as of January 2026. Verbatim:

“13 state Medicaid programs covered GLP-1s for obesity treatment under fee-for-service as of January 2026.”

Florida is NOT named among either the 13 states covering GLP-1s for obesity or the 4 states (California, New Hampshire, Pennsylvania, South Carolina) that eliminated coverage between October 2025 and January 2026. Florida's absence from the “13 states covering” list is the operative KFF finding for this article. The primary-source finding — PDL absence + GLP-1 Criteria silence — is consistent with and corroborated by the KFF absence.

The four-state taxonomy: how Florida compares to Texas, California, and New York

Our 50-state Medicaid GLP-1 series has now audited four large states. Each has a structurally distinct coverage posture.

Florida's “silent exclusion” model is the most distinctive in the four-state cluster. The coverage stance is real — no PA pathway exists, and all major SMMC plans defer to the AHCA PDL — but the absence of an explicit AHCA non-coverage bulletin means that a policy-level change (if AHCA were to add Wegovy or Zepbound to the PDL at a future P&T Committee meeting) could happen without a major legislative instrument or a separate regulatory amendment. The quarterly P&T Committee cycle is the operative decision mechanism.

Excluded populations: who this article's analysis does not apply to

The coverage analysis in this article applies to Florida Medicaid recipients enrolled in SMMC 3.0 managed-care plans (Sunshine Health, Humana Healthy Horizons, Simply Healthcare, Molina Healthcare, Aetna Better Health). The following populations may have different pharmacy-benefit structures or separate coverage rules:

• Fee-for-service (FFS) Medicaid: A small subset of Florida Medicaid recipients remain in fee-for-service (FFS) outside the SMMC program (e.g., certain long-term-care populations, dually eligible Medicare-Medicaid beneficiaries under specific carve-outs). FFS pharmacy claims are adjudicated against the AHCA PDL directly — the same PDL analyzed here — but plan-level PA administration differs.
• Dental-only, vision-only, and specialty plans: Florida Medicaid's specialty plans (dental HMOs, vision plans) do not administer outpatient pharmacy benefits. This article does not apply to those plan types.
• Long-Term Care (LTC) plans and SMMC LTC component: Long-term care services are administered through a separate SMMC LTC component. GLP-1 outpatient pharmacy benefits for LTC plan enrollees are adjudicated through the plan's pharmacy benefit — which references the same AHCA PDL — but individual LTC plan-level rules should be verified directly.
• Children under age 10 (for Ozempic and Rybelsus): The Florida Medicaid GLP-1 PA Criteria set a minimum age of 18 for Ozempic and Rybelsus. Children under 10 are also below the minimum age for Mounjaro and Trulicity. The EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) benefit may provide a case-by-case pathway for medically necessary treatments not on the PDL for Medicaid beneficiaries under 21 — but no verbatim Florida-specific EPSDT + GLP-1 primary source is available.
• Dual-eligible Medicare-Medicaid beneficiaries: Dual-eligibles enrolled in Medicare Part D have their pharmacy benefit administered primarily through Part D. Beginning July 1, 2026, the CMS Medicare GLP-1 Bridge provides Part D coverage of Wegovy and Zepbound KwikPen for eligible Medicare beneficiaries (BMI ≥ 27 plus heart disease or prediabetes). The Part D bridge does not depend on Florida Medicaid PDL status.

If your Florida Medicaid GLP-1 PA is denied: the Fair Hearing pathway

Florida Medicaid members whose GLP-1 prior authorization is denied have the right to a Fair Hearing administered through the Florida Department of Children and Families (DCF) / Office of Medicaid Hearings and Compliance (OMC) framework.

The Fair Hearing process

1. Receive the Notice of Action (NOA). Your SMMC plan is required to issue a written NOA when it denies, reduces, or terminates a pharmacy benefit. The NOA must state the reason for denial with the specific coverage criterion cited.
2. Request a Fair Hearing within the deadline. Florida Medicaid fair-hearing rights typically allow 90 days from the date of the NOA to request a hearing. Members already receiving the denied medication may request an expedited hearing; aid-paid-pending continuation of the drug while the hearing is pending may be available if the request is filed within 10 days of the NOA and the member was previously approved.
3. File with DCF / OMC. Hearing requests can be submitted to the Florida Department of Children and Families. Your plan's NOA must include hearing-request instructions. Keep copies of all documentation.
4. Prepare the medical record package. For T2D- indication GLP-1 denials, gather: (a) documented T2D diagnosis with ICD-10-CM code; (b) HbA1c result ≥ 6.5% within the prior 6 months; (c) documentation of metformin trial-and-failure or contraindication within the prior 2 years; (d) for non-preferred drugs, documentation of previous trial of a preferred GLP-1 with insufficient response or adverse reaction.

Adjudication-error appeals vs policy-level appeals: what a Fair Hearing can and cannot fix

The distinction between adjudication-error appeals and policy-level appeals is critical for setting realistic expectations.

Patient action steps

Step 1 — Verify Florida Medicaid enrollment and SMMC plan assignment

Florida Medicaid income and asset eligibility is determined by the Department of Children and Families (DCF). Most adults with income at or below 138% of the federal poverty level are eligible. To verify eligibility and determine which SMMC plan you are enrolled in:

• Visit myflorida.com or call the Florida Medicaid member helpline.
• Log into your SMMC plan's member portal to confirm your current prescription drug coverage structure and PA submission process.
• Confirm whether you are enrolled in an SMMC plan or in fee-for-service Medicaid — this affects which entity administers your PA.

Step 2 — If you have T2D, prepare the Clinical PA documentation package

For T2D-indicated GLP-1 PA (Mounjaro, Ozempic, Trulicity), your prescriber must submit documentation demonstrating:

• Diagnosis of type 2 diabetes mellitus (with ICD-10-CM code).
• HbA1c ≥ 6.5% measured within the past 6 months (lab report required).
• Trial and failure of metformin within the past 2 years, or documented contraindication or intolerance (progress note or allergy documentation required).
• For non-preferred agents (Rybelsus, Victoza, Exenatide): documented previous trial of a preferred GLP-1 with insufficient response, adverse reaction, or contraindication.
• Patient age meeting the minimum threshold: ≥ 18 for Ozempic / Rybelsus; ≥ 10 for Mounjaro / Trulicity / Victoza.

PA forms are available at the AHCA Pharmacy PA Forms page: ahca.myflorida.com/medicaid/prescribed-drugs/medicaid-pharmaceutical-therapeutics-committee/pharmacy-prior-authorization-forms.

Step 3 — If you need GLP-1s for weight loss (not T2D): cash-pay and alternative options

Florida Medicaid does not cover Wegovy, Zepbound, or Saxenda for chronic weight management under the current April 1, 2026 PDL. Patients seeking GLP-1 therapy for weight loss without a T2D diagnosis have limited options:

• NovoCare Patient Access Program: Novo Nordisk offers a $299/month Wegovy co-pay card for commercially insured patients meeting eligibility criteria. Medicaid patients are not eligible for most commercial co-pay programs, but income-based patient assistance may be available for uninsured patients below an income threshold. Contact NovoCare at 1-833-NOVO4ME.
• LillyDirect: Eli Lilly's direct patient access program offers Zepbound at $399-$549/month for the standard pens, or Foundayo (oral orforglipron) starting at $149/month for eligible patients who meet income criteria. Medicaid patients may be eligible for Lilly Cares Foundation patient assistance; verify directly at lillyinsulin.com or lillymedicares.com.
• GoodRx and pharmacy discount cards: GoodRx and similar discount programs may reduce out-of-pocket costs at retail pharmacies. These are cash-pay programs; they cannot be combined with Medicaid coverage.
• Telehealth GLP-1 programs: Several telehealth providers offer GLP-1 prescriptions with bundled cash-pay pricing. Medicaid patients using telehealth GLP-1 programs must be aware that Florida Medicaid does not reimburse these claims; all payment is out-of-pocket.

Further reading

• Top GLP-1 insurance-coverage questions on Reddit, answered
• GLP-1 contraindications cheat sheet